Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients-Reference-Cited by-同舟云学术

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients

Published:2018-12-04 Issue:3 Volume:24 Page:274-287
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Mukai Hirofumi,Shimizu Chikako,Masuda Norikazu,Ohtani Shoichiro,Ohno Shinji,Takahashi Masato,Yamamoto Yutaka,Nishimura Reiki,Sato Nobuaki,Ohsumi Shozo,Iwata Hiroji,Mori Yuko,Hashigaki Satoshi,Muramatsu Yasuaki,Nagasawa Takashi,Umeyama Yoshiko,Lu Dongrui R.,Toi Masakazu

Funder

Pfizer

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-018-1353-9.pdf

Reference35 articles.

1. Nakamura K, Okada E, Ukawa S et al (2017) Characteristics and prognosis of Japanese female breast cancer patients: The BioBank Japan project. J Epidemiol 27(S3):S58–S64. https://doi.org/10.1016/j.je.2016.12.009

2. American Cancer Society (2017) Breast Cancer Facts & Figures 2017–2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf . Accessed July 17 2018

3. Aihara T, Toyama T, Takahashi M et al (2016) The Japanese Breast Cancer Society Clinical practice guideline for systemic treatment of breast cancer, 2015 edition. Breast Cancer 23(3):329–342. https://doi.org/10.1007/s12282-016-0670-y

4. Cardoso F, Costa A, Norton L et al (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25(10):1871–1888. https://doi.org/10.1093/annonc/mdu385

5. Fry DW, Harvey PJ, Keller PR et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3(11):1427–1438

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis;BMC Cancer;2024-08-21

2. Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study;Breast Cancer;2024-04-20

3. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients;The Oncologist;2023-11-23

4. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial;The Oncologist;2023-11-16

5. Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole;Breast Cancer;2023-10-26